AMAP-102 is a serotonin 5-HT2B and 5-HT2C receptor antagonist which is or was under development for the treatment of musculoskeletal pain and rheumatoid arthritis.[1][2][3] It is taken by mouth.[1]
| Clinical data | |
|---|---|
| Other names | AMAP102 |
| Routes of administration | Oral[1] |
| Drug class | Serotonin 5-HT2B receptor antagonist; Serotonin 5-HT2C receptor antagonist |
The drug is or was under development by AnaMar AB.[1][2][3] A phase 1 clinical trial was completed in 2009 and the results of a phase 2 trial were reported in 2014.[1] It failed to reduce inflammatory pain in people with osteoarthritis in this trial and its development was said to have been discontinued.[1] However, the drug is still listed as being in active development as of January 2025.[2][3] The chemical structure of AMAP-102 does not appear to have been disclosed.[1][2][3]
References
edit- ^ a b c d e f g Wang Q, Zhou Y, Huang J, Huang N (January 2021). "Structure, Function, and Pharmaceutical Ligands of 5-Hydroxytryptamine 2B Receptor". Pharmaceuticals (Basel). 14 (2): 76. doi:10.3390/ph14020076. PMC 7909583. PMID 33498477.
- ^ a b c d "AMAP 102". AdisInsight. 4 November 2017. Retrieved 14 January 2025.
- ^ a b c d "Delving into the Latest Updates on AMAP-102 with Synapse". Synapse. 21 November 2024. Retrieved 14 January 2025.
 | This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |